Ocular Therapeutix (NSDQ:OCUL) announced today that its Phase 2 clinical trial for treating dry eye disease (DED) did not meet its primary endpoint. Bedford, Massachusetts-based Ocular Therapeutix's U.S.-based, randomized, double-masked, … [Read More...] about Ocular Therapeutix dry eye treatment trial fails to meet primary endpoint
Main Content
Sponsored Content
Noble expands its services for its clients into Human Factors
Human Factors + (HF+) is a natural extension of Noble’s deep understanding of the patient experience relative to self-administering drug therapies By Tim McLeroy, Executive Director of Marketing … [Read More...] about Noble expands its services for its clients into Human Factors
Featured Posts
FDA approves Genentech’s Susvimo drug-eluting eye implant
Genentech announced today that it received FDA approval for its Susvimo injection for treating macular degeneration (AMD). South San Francisco-based Genentech, a member of the Roche Group, designed its Susvimo ranibizumab injection (100 mg/mL) for … [Read More...] about FDA approves Genentech’s Susvimo drug-eluting eye implant
Ocular Therapeutix dry eye treatment trial fails to meet primary endpoint
Ocular Therapeutix (NSDQ:OCUL) announced today that its Phase 2 clinical trial for treating dry eye disease (DED) did not meet its primary endpoint. Bedford, Massachusetts-based Ocular Therapeutix's U.S.-based, randomized, double-masked, … [Read More...] about Ocular Therapeutix dry eye treatment trial fails to meet primary endpoint
Eli Lilly touts data for tirzepatide compared to insulin glargine for type 2 diabetes
Eli Lilly (NYSE:LLY) announced positive results from a trial comparing tirzepatide to titrated insulin glargine in adults with type 2 diabetes. Indianapolis-based Eli Lilly's Surpass-4 clinical trial demonstrated that adults with type 2 diabetes … [Read More...] about Eli Lilly touts data for tirzepatide compared to insulin glargine for type 2 diabetes
Medtronic touts data for MiniMed 780G insulin pump in children
Medtronic (NYSE:MDT) reported positive one-year, real-world clinical data for its MiniMed 780G insulin pump platform in children. Data came from a subset of 3,211 pediatric and adolescent patients (15 years old and below) with type 1 diabetes … [Read More...] about Medtronic touts data for MiniMed 780G insulin pump in children
Phillips-Medisize expands its global manufacturing capacity
Phillips-Medisize announced today that it expanded its global manufacturing capacity through several collaborations and internal initiatives. Hudson, Wisconsin-based Phillips-Medisize, a Molex company, said its global reach now encompasses 36 … [Read More...] about Phillips-Medisize expands its global manufacturing capacity
Ultrahuman hires chief business officer as it scales expansion for glucose monitoring tech
Metabolic tracking technology developer Ultrahuman announced today that it appointed Bhuvan Srinivasan as its first chief chief business officer. The appointment of Srinivasan to the new role follows Bangalore, India-based Ultrahuman's $17.5 … [Read More...] about Ultrahuman hires chief business officer as it scales expansion for glucose monitoring tech
Insulet announces board of director changes
Insulin delivery technology developer Insulet (NSDQ:PODD) announced today that it appointed Dr. Luciana Borio to its board of directors. Borio joins the board of Acton, Massachusetts–based Insulet, having served in key roles with the FDA, the … [Read More...] about Insulet announces board of director changes
Report: Medtronic in negotiations to buy Israel-based insulin pump maker Triple Jump
Reports in Israel say that Medtronic (NYSE:MDT) has entered talks to acquire Triple Jump for $300 million. Calcalist reported that the proposed acquisition, which is in advanced negotiations, follows a 2020 investment into Triple Jump made by … [Read More...] about Report: Medtronic in negotiations to buy Israel-based insulin pump maker Triple Jump
Navidea names two appointments to its board of directors
Navidea Biopharmaceuticals (NYSE:NAVB) announced today that it appointed two new members to its board of directors. Thomas Forest Farb-Horch and Agnieszka Winkler joined Dublin, Ohio-based Navidea's board, effective Oct. 7, each with a three-year … [Read More...] about Navidea names two appointments to its board of directors
Corium touts study results for once-daily ADHD capsule
Corium (NSDQ:CORI) today announced clinical data demonstrating the strong performance of its once-daily ADHD capsule. Boston-based Corium's Azstarys oral capsule for treating ADHD symptoms (serdexmethylphenidate [SDX] and dexmethylphenidate … [Read More...] about Corium touts study results for once-daily ADHD capsule
In case you missed it
- Dexcom announces Garmin as first partner for real-time APIs
- Insulet CEO Shacey Petrovic touts Omnipod 5, expects device launch this year
- Metabolic disease reversal tech company Twin Health raises $140M Series C
- MedAlliance touts 18-month data for treating lesions with sirolimus-eluting balloon
- New BD syringe manufacturing lines are up and running in Nebraska
- FDA offers expanded clearance for DreaMed’s AI-based support system for type 2 diabetes
- BREAKING: Medtronic expands Class I recall of MiniMed 600 series insulin pumps
- Stevanato Group is constructing a new facility in Indiana
- Insulet reports positive study results for Omnipod 5
- FDA clears BreatheSuite’s device to turn regular metered-dose inhalers into smart inhalers
- MedAlliance completes trial enrollment for sirolimus-eluting balloon for treating PAD
- Thermo Fisher authorizes $3B in share repurchases
- FDA approves Baxter’s norepinephrine injection for treating low blood pressure
- Merck and Vesselon preclinical study reports dramatic tumor pharmacokinetics findings
- BD says glass prefillable syringes still perform after deep cold storage
Clinical Trials
Ocular Therapeutix dry eye treatment trial fails to meet primary endpoint
Ocular Therapeutix (NSDQ:OCUL) announced today that its Phase 2 clinical trial for treating dry eye disease (DED) did not meet its primary endpoint. Bedford, Massachusetts-based Ocular Therapeutix’s U.S.-based, randomized, double-masked, multi-center, vehicle-controlled Phase 2 clinical trial evaluated OTX-CSI (cyclosporine intracanalicular insert) for treating DED by measuring signs and symptoms of DED in 140 subjects treated […]
Eli Lilly touts data for tirzepatide compared to insulin glargine for type 2 diabetes
Eli Lilly (NYSE:LLY) announced positive results from a trial comparing tirzepatide to titrated insulin glargine in adults with type 2 diabetes. Indianapolis-based Eli Lilly’s Surpass-4 clinical trial demonstrated that adults with type 2 diabetes and increased cardiovascular (CV) risk experienced superior A1C and body weight reductions from baseline across all three doses of tirzepatide compared […]
Medtronic touts data for MiniMed 780G insulin pump in children
Medtronic (NYSE:MDT) reported positive one-year, real-world clinical data for its MiniMed 780G insulin pump platform in children. Data came from a subset of 3,211 pediatric and adolescent patients (15 years old and below) with type 1 diabetes using the MiniMed 780G system with the Guardian Sensor 3 in Europe. According to a news release, the […]
AbbVie receives positive opinion from CHMP for injection that treats psoriatic arthritis
AbbVie (NYSE:ABBV) announced today that a European governing body recommended approval for its psoriatic arthritis treatment injection. The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of risankizumab (SKYRIZI, 150 mg, subcutaneous injection at week 0, week 4 and every 12 weeks thereafter) alone or in combination with […]
Corium touts study results for once-daily ADHD capsule
Corium (NSDQ:CORI) today announced clinical data demonstrating the strong performance of its once-daily ADHD capsule. Boston-based Corium’s Azstarys oral capsule for treating ADHD symptoms (serdexmethylphenidate [SDX] and dexmethylphenidate [d-MPH]) received FDA approval in March as the first and only product containing a d-MPH oral prodrug for treating ADHD (attention deficit hyperactivity disorder) symptoms in patients […]
